Protagonist Therapeutics (PTGX) Tops Q2 EPS by 10c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.50), $0.10 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $4.17 million versus the consensus estimate of $68 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• DOJ Unveils $6.5B Healthcare Fraud Crackdown - WSJ
• Quantum Computing Inc (QUBT) call put ratio 6.5 calls to 1 put with a focus on June 26 weekly 12.50 calls as share price up 3.1%